TransCyte

TransCyte®

Surgery Biosynthetic temporary skin substitute wound covering for treating severe burn, protecting the wound bed, promoting healing and ↓ side effects of allografts. See Artificcial skin.
References in periodicals archive ?
The use of temporary skin substitutes such as Biobrane, TransCyte, Integra and Terudermis have become more widely used in the treatment of mild to deep dermal burn injury.
But staff at a specialist burns centre at the University of California managed to cover her entire body with a skin substitute, called TransCyte.
During the race to save Yeargain's life, medical staff covered her body with an artificial skin called transcyte and gave her medication to stop the internal bleeding Lozano said the transcyte allowed rapid healing, adding: ``Within about a week her own skin was back.
Now in clinical trials, TransCyte is a skin replacement product derived from cells harvested from the inner skin layer.
The first covers the application of Advanced Tissue Sciences' tissue engineering technology for skin wounds and includes Dermagraft for the treatment of diabetic foot ulcers, TransCyte for the temporary covering of second and third-degree burns, and future developments for venous ulcers, pressure ulcers, burns and other non-aesthetic wound care treatments.
A dozen A4 sized pieces of Transcyte - laboratory grown, wafer-thin skin replacement - were rushed to St Mary's along with 150 tubes of burns treatment Flamezine.
The company, through its Dermagraft Joint Venture with Smith & Nephew plc, currently has two products on the market, TransCyte, a temporary covering for full (third-degree) and partial-thickness (second-degree) burns, and Dermagraft, a living dermal replacement for the treatment of diabetic foot ulcers (currently available in Canada and the United Kingdom).
It previously also offered Dermagraft and TransCyte tissue engineering products but, in October 2005, S&N announced it would exit these operations due to delays in the products achieving economic viability.
The Company is focused on the commercialization of cell-based and tissue-engineered products including two that have FDA approval for marketing: Dermagraft, for diabetic foot ulcers and TransCyte, to treat full and partial thickness burns.
Privately held, ABH has two approved products: Dermagraft and TransCyte.
We are encouraged by the first half performance of Dermagraft, our bioengineered skin replacement for diabetic foot ulcers, as well as TransCyte, used to treat burn patients.
We also acquired the remaining half of our Dermagraft and TransCyte joint arrangements from Advanced Tissue Sciences, Inc.
Full browser ?